CHL1 and metabolic dysfunction-associated steatotic liver disease: On the other hand, the squalene-reduced expression of CHL1 impairs insulin secretion [54,55], thus activating the production of hepatic triglyceride-rich lipoproteins [56] and consequent NAFLD [57,58].